ImmunityBio, Inc.'s advances with Anktiva & rBCG show promise amid financial hurdles. Click here to find out why IBRX stock ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: SES AI Corp (SES) 118.91% +9.28, Microvision ...

Teacher Retirement System of Texas grew its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 20.4% in the ...

CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...

D. Boral Capital reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report issued on Monday,Benzinga reports. They currently have a $30.00 target price on the stock.

We recently published a list of 10 Stocks Outperform Broader Market Last Week. In this article, we are going to take a look ...

ImmunityBio, Inc.’s IBRX share price has surged by 20.86%, which has investors questioning if this is right time to sell.

“ImmunityBio commenced 2025 with notable scientific and business milestones,” said Richard Adcock, President and CEO of ImmunityBio. “With a promising future ahead, we are eager to engage with our ...

We recently published a list of Top 10 Penny Stocks That Will Skyrocket. In this article, we are going to take a look at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SAN DIEGO, CA - ImmunityBio, Inc. (NASDAQ:IBRX), a biotechnology company specializing in biological products, announced a change in its certifying accountant, as disclosed in a recent 8-K filing with ...

SAN DIEGO, CA - ImmunityBio, Inc. (NASDAQ:IBRX), a biotechnology company specializing in biological products, announced a change in its certifying accountant, as disclosed in a recent 8-K filing ...